Welcome to our dedicated page for Ani Pharmaceutic news (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on Ani Pharmaceutic stock.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company with an active flow of corporate, clinical, and financial news. The company develops, manufactures, and commercializes therapeutics through its Rare Disease, Generics, and Brands businesses, and its communications frequently highlight progress in these areas. Investors following ANIP news can track how the Rare Disease segment, including products such as ILUVIEN and Purified Cortrophin Gel, contributes to the company’s growth alongside its generics and branded drug portfolios.
News updates for ANI often cover financial results and guidance, including quarterly earnings releases, adjusted non-GAAP metrics, and full-year outlooks. Press releases and related Form 8-K filings provide detail on net revenues by segment, the performance of key products, and management’s commentary on business trends. These disclosures also outline how Rare Disease revenues, particularly from Cortrophin Gel and ILUVIEN, compare with contributions from Generics and Brands.
ANIP news also includes clinical and medical developments, such as results from the NEW DAY clinical trial of ILUVIEN in diabetic macular edema and their presentation at major ophthalmology and retina meetings. The company reports on initiatives like the FutureVision Advisory Council, a group of retina and uveitis specialists formed to help guide its ophthalmology and retina franchise. Updates on Phase 4 trials, label transitions, and adoption trends for ILUVIEN and related products are also featured.
In addition, ANI regularly announces corporate and governance updates, including board transitions and leadership roles, as well as participation in healthcare and investor conferences hosted by organizations such as J.P. Morgan, Piper Sandler, Jefferies, H.C. Wainwright, and Morgan Stanley. These events often involve presentations or fireside chats where management discusses strategy, the transformation toward a rare disease–focused profile, and capital allocation priorities.
By monitoring ANIP news, readers can follow developments across rare disease therapeutics, generics, branded products, clinical research, and capital markets activity, all of which shape the company’s trajectory.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will release its second quarter 2022 financial results on August 8, 2022, before market open. A conference call will be hosted by President Nikhil Lalwani and CFO Stephen P. Carey at 8:00 a.m. ET. Investors can join the call by dialing 800-225-9448 or via webcast at www.anipharmaceuticals.com. A replay will be available shortly after the call for two weeks. ANI focuses on developing and marketing prescription pharmaceutical products addressing high unmet medical needs.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announces the appointment of Meredith W. Cook as SVP, General Counsel, and Corporate Secretary, effective July 18. With over 20 years of experience in the pharmaceutical sector, Ms. Cook's expertise includes corporate governance and mergers and acquisitions. Nikhil Lalwani, President and CEO, expressed confidence in her ability to significantly contribute to the company's growth, especially in launching the Purified Cortrophin® Gel. Ms. Cook previously held key legal roles at Amneal Pharmaceuticals and Dr. Reddy’s Laboratories.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) has received FDA approval for its Clorazepate Dipotassium Tablets, a generic version of Tranxene®. The U.S. market for this product is approximately $25.8 million, as reported by IQVIA/IMS Health. CEO Nikhil Lalwani highlighted this launch as part of ANI's commitment to expanding access to essential therapeutics. The Company continues to focus on sustainable growth through new product launches and strengthening its generics portfolio.
ANI Pharmaceuticals and Veeva Systems have partnered to enhance commercial strategies for ANI's Rare Disease Business Unit, utilizing Veeva's data-driven tools. This collaboration aims to launch ANI's first product, Purified Cortrophin Gel, in the U.S. The companies emphasize agility and precision in addressing rare disease patients' needs. ANI has adopted Veeva Commercial Cloud solutions to strengthen its sales and marketing capabilities. This partnership is expected to refine customer engagement and optimize sales interactions, marking a significant step in ANI's mission to improve patient access.
ANI Pharmaceuticals plans to cease operations at its Oakville, Ontario manufacturing plant by Q1 2023 as part of cost-competitiveness efforts following its acquisition of Novitium Pharma in November 2021. This move is expected to enhance profitability and cash flow by $7 million to $8 million annually. Products from the Oakville site will be transitioned to U.S. facilities, ensuring supply continuity. The company remains committed to treating employees respectfully and is exploring potential buyers for the Oakville site.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) has received FDA approval for its Abbreviated New Drug Application (ANDA) for Fludrocortisone Acetate Tablets USP, 0.1 mg, a generic version of Florinef®. The U.S. market for these tablets is valued at approximately $24.2 million, according to IQVIA/IMS Health. This marks ANI's continued commitment to delivering generic products in limited competition markets, showcasing the strength of its R&D capabilities. The company aims to leverage this approval to enhance its market presence and revenue potential.
ANI Pharmaceuticals (NASDAQ: ANIP) announced that CEO Nikhil Lalwani and CFO Stephen Carey will present at two key conferences. The first, the H.C. Wainwright Global Investment Conference, is a virtual event on May 24, 2022 at 7:00 a.m. ET. The second is the Jefferies Healthcare Conference in New York City on June 9, 2022 at 11:30 a.m. ET. Webcasts will be available on the company's website, enhancing transparency and investor engagement.
ANI Pharmaceuticals reported first quarter 2022 net revenues of $64.5 million, a 17.6% increase from Q1 2021. However, the company faced a net loss of $(20.1) million, equating to a diluted GAAP loss per share of $(1.27). Adjusted non-GAAP EBITDA was $4.3 million. The company provided revenue guidance for Cortrophin Gel of $35 million to $40 million and total net revenue guidance of $295 million to $315 million for 2022. Strong physician demand for Cortrophin Gel has resulted in over 250 new cases initiated. ANI's ongoing R&D efforts led to several new product launches and six new ANDA applications.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will release its Q1 2022 financial results on May 10, 2022. A conference call will follow at 8:30 a.m. ET to discuss these results. The call can be accessed via a toll-free number and a webcast available on their website. ANI focuses on developing, manufacturing, and marketing high-quality branded and generic pharmaceuticals, aiming for sustainable growth through its Purified Cortrophin™ Gel franchise and enhanced generics business.
ANI Pharmaceuticals has launched Misoprostol Tablets in 100 mcg and 200 mcg strengths, positioned as the generic counterpart to Cytotec®.
The U.S. market for these tablets is valued at approximately $15.3 million. The product holds an AB rating, ensuring its bioequivalence to the reference drug, which enhances its competitive edge amidst a recent market shortage.
ANI aims to fulfill the demand for limited market competition in generics, emphasizing its commitment to patient needs and sustainable growth.